Bristol-Myers Again Rebuffs Plavix Fraud Claims

Law360, New York (January 8, 2008, 12:00 AM EST) -- Under fire from investors who insist they've sufficiently pled scienter, Bristol-Myers Squibb Co. is bolstering its bid to toss the suit that says it misled shareholders with the Plavix patent deal, under scrutiny for its impact on competition, that it made with Apotex Corp.

In its reply Monday in support of its earlier motion to get the securities litigation dismissed, Bristol-Myers disputed its investors' claim that its promises to "vigorously pursue" enforcement of its patents against Apotex were tantamount to deception.

According to the suit, they...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.